Precision Optics Corporation, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a POCI research report →
Price Chart
About the company
Precision Optics Corporation, Inc. (POCI) specializes in the engineering, manufacturing, and sale of advanced optical and illumination systems, along with their complementary components. Its main operational regions are the United States and the European Economic Area.
- CEO
- Joseph N. Forkey
- IPO
- 1992
- Employees
- 108
- HQ
- Littleton, MA, US
Get TickerSpark's AI analysis on POCI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $45.30M
- P/E
- -14.21
- Fwd P/E
- 137.33
- PEG
- -0.13
- P/S
- 1.39
- P/B
- 2.27
- EV/EBITDA
- -18.07
- Div Yield
- 0.00%
- Gross Margin
- 19.16%
- Op Margin
- -7.37%
- Net Margin
- -7.48%
- ROE
- -14.10%
- ROIC
- -9.98%
Latest fiscal year · YoY change
- Revenue
- $31.53M+65.2%
- Gross Profit
- $5.43M+59.5%
- Op Income
- $-3,508,608
- Net Income
- $-3,629,891+37.2%
- EPS
- $-0.43+49.4%
- OCF Growth
- +56.3%
- FCF Growth
- +47.6%
- 52W High
- $6.15
- 52W Low
- $3.55
- 50D MA
- $4.53
- 200D MA
- $4.61
- Beta
- 0.34
- RSI (14)
- 36
- Avg Volume
- 43.96K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Precision Optics posted strong year-over-year improvement in Q1, but a satellite customer slowdown will pressure Q2 before growth is expected to reaccelerate in the second half.· November 16, 2026
- Revenue was $8.2 million, up 22% year over year but down from the prior quarter’s record $8.8 million.
- Gross margin improved to 22.5% from 14.2% a year ago, helped by higher production volume and better manufacturing efficiency.
- Adjusted EBITDA loss narrowed to about $200,000 versus a $1.2 million loss last year, though management said Q2 will be the weakest quarter.
- The company reiterated FY2027 guidance of $30 million to $33 million revenue and an adjusted EBITDA loss of $1.2 million to $1.7 million.
- Management said two programs have already moved from development to production this year, with two more expected to follow over the next 6 to 9 months.
First-quarter fiscal 2027 revenue was $8.2 million, up from $6.7 million a year ago and down from $8.8 million in Q4 fiscal 2026. Gross profit was about $1.8 million, with gross margin of 22.5% versus 14.2% last year; operating loss was $518,000 versus about $1.6 million, net loss was about $475,000 or $0.04 per share versus $1.6 million or $0.21 per share, and adjusted EBITDA was a loss of about $200,000 versus a $1.2 million loss a year ago. Ending cash and cash equivalents were about $9 million, with total bank debt of about $1.1 million. For fiscal 2027, management reiterated revenue guidance of $30 million to $33 million and adjusted EBITDA loss guidance of $1.2 million to $1.7 million; they expect Q2 to be the most challenging quarter, with recovery in the second half.
Joe Forkey emphasized that the quarter showed the benefits of prior investments in production capacity, manufacturing efficiency, and the broader operating team. He framed the satellite customer slowdown as temporary and said the company now has better visibility after receiving a follow-on order, with revenue expected to recover in Q3 and Q4. He was upbeat about the pipeline, saying four programs are expected to transition to production this fiscal year and highlighting new opportunities in medical devices, satellite communications, and adjacent markets such as AI-related optics.
Wayne Coll focused on the financial bridge from last year to this quarter: revenue rose to $8.2 million, gross profit increased to about $1.8 million, gross margin expanded to 22.5%, and adjusted EBITDA improved to a roughly $200,000 loss. He said production revenue reached $7.4 million, led by systems manufacturing at about $5.8 million, micro-optics lab revenue of about $306,000, and Ross Optical at about $1.3 million. He also noted that operating expenses were about $2.4 million, cash ended at about $9 million, and the company is holding guidance unchanged despite expecting Q2 to be the toughest quarter.
Analysts asked how much the single-use endoscope programs could contribute over time and how gross margin should trend as the revenue mix changes. Management said the cystoscope program has leveled off somewhat but still supports bottom-line contribution, the ophthalmic line could easily double in the next couple of quarters, and the microarthroscope should start around $100,000 a quarter before growing. On margins, management said the mix shift toward micro-optics, Ross Optical, and improved engineering utilization is constructive, but satellite demand will weigh on Q2 before margins improve again later in the year.
The call presented a clear path back to record quarterly revenue after the current satellite pause, supported by a follow-on order and expected recovery in Q3 and Q4. Management also described a growing base of production programs, improving gross margin, and a broader pipeline that could expand as the sales organization improves and more programs move from development to production.
Near-term results still depend heavily on one satellite customer, and management said Q2 will be the weakest quarter with a larger adjusted EBITDA loss than Q1. They also flagged uncertainty around launch timing, the pace of satellite program recovery, and whether new opportunities in areas like AI data centers and airborne/ground optical communications will materialize soon enough to offset the current dip.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 72.4%
- Shares Outstanding
- 10.97M
- Float Shares
- 7.95M
of shares held by institutions
31 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Needham Investment Management LLC | 1.67M | 0 |
| Vanguard Capital Management LLC | 325.75K | 0 |
| Nantahala Capital Management, LLC | 280.00K | 0 |
| Wealthtrust Axiom LLC | 249.54K | ▼ 10.92K |
| Vanguard Group Inc | 223.47K | ▲ 1.60K |
| Myda Advisors LLC | 216.00K | ▼ 159.00K |
| Morgan Stanley | 175.69K | ▼ 4.00K |
| Hightower Advisors, LLC | 124.34K | 0 |
| Geode Capital Management, LLC | 77.68K | ▲ 11.54K |
| Renaissance Technologies LLC | 59.30K | ▲ 5.20K |
| Vanguard Fiduciary Trust Co | 54.69K | ▲ 15.94K |
| Citadel Advisors LLC | 31.03K | ▼ 10.70K |
Held by 22 ETFs
Biggest fund positions in POCI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 30, 26 | COLL WAYNE M | other | 1,412 |
| Sep 30, 26 | COLL WAYNE M | other | 6,250 |
| Sep 21, 26 | Forkey Joseph Norman | other | 6,742 |
| Sep 21, 26 | COLL WAYNE M | other | 6,742 |
| Sep 21, 26 | TRAUT JOSEPH | other | 6,742 |
| Aug 18, 26 | Thier Peter Richard | other | 50,000 |
| Aug 18, 26 | Thier Peter Richard | other | 0 |
| Jun 30, 26 | COLL WAYNE M | other | 1,257 |
| Mar 27, 26 | NEEDHAM INVESTMENT MANAGEMENT LLC | other | 0 |
| Mar 31, 26 | COLL WAYNE M | other | 1,568 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our POCI coverage
Recent articles, reports, and earnings notes.
No research on POCI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate POCI report →Precision Optics Corporation, Inc. (POCI) Q1 2027 Earnings Call Transcript
seekingalpha.com · Nov 18
Precision Optics Q1 Earnings Call Highlights
marketbeat.com · Nov 16
Precision Optics Reports First Quarter Fiscal 2027 Financial Results
globenewswire.com · Nov 16
Precision Optics Schedules First Quarter Fiscal 2027 Conference Call for November 16, 2026
globenewswire.com · Nov 9
Precision Optics Announces $2 Million Follow-On Order from Existing Top-Tier Aerospace Customer
globenewswire.com · Nov 5
Integra LifeSciences (NASDAQ:IART) & Precision Optics (NASDAQ:POCI) Critical Review
defenseworld.net · Oct 12
Precision Optics to Participate in the Lytham Partners Fall 2026 Investor Conference
globenewswire.com · Sep 29
Precision Optics Corporation, Inc. (POCI) Q4 2026 Earnings Call Transcript
seekingalpha.com · Sep 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.